Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Requires companies to disclose where medicines and drugs come from.
The problem
Americans may not know if their drugs are made in the U.S. or other countries. This lack of transparency raises concerns about drug safety, quality control, and supply chain reliability.
The proposal
The bill would require pharmaceutical companies to provide clear information about the origin and manufacturing location of drugs sold in America.
The impact
Patients, healthcare providers, and government agencies would gain transparency about drug sources. Pharmaceutical companies would need to track and report manufacturing information.
Patients and doctors could make informed choices about medications. People would know where their drugs are manufactured and could assess quality based on that information.
Tracking drug origins helps protect against counterfeit medications and supply chain threats. It strengthens U.S. preparedness for health emergencies by identifying domestic versus foreign dependencies.
Transparency encourages companies to maintain consistent manufacturing standards. It creates accountability for drug safety across different production locations.
Information about drug origins may encourage support for U.S.-based pharmaceutical manufacturers. This could boost American drug production capacity and jobs.
Pharmaceutical companies must implement new tracking and reporting systems. These administrative costs could be passed to consumers through higher drug prices.
Labeling requirements might disadvantage foreign manufacturers and could trigger trade disputes. Other countries may view this as unfair discrimination against their products.
Many drugs use ingredients from multiple countries, making origin tracking complicated. Determining a single 'origin' may be difficult for complex pharmaceutical products.
Labeling drugs by origin could create unfounded bias against certain countries' products. Consumers might avoid safe medications based on misconceptions about foreign manufacturing.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.